ZVRA
HealthcareZevra Therapeutics, Inc.
$8.34
+$0.00 (+0.00%)
Jan 5, 2026
Price History (1Y)
Analysis
Zevra Therapeutics, Inc. operates within the healthcare sector, specifically in the biotechnology industry. With a market capitalization of $469.52M and revenue of $84.39M (TTM), the company has established itself as a mid-sized player in this space. Additionally, ZVRA employs 59 individuals. From a financial perspective, Zevra Therapeutics demonstrates a gross margin of 80.7%, indicating robust profitability in its core business operations. The company's operating and profit margins stand at 15.9% and 41.9%, respectively. However, it is worth noting that the EBITDA figure shows a loss of $-23,624,000. On the balance sheet side, ZVRA maintains a current ratio of 8.62 and holds cash reserves totaling $199.51M while carrying debt of $62.72M. In terms of valuation context, Zevra Therapeutics' P/E ratio stands at 17.74 (TTM) and forward P/E is 13.45. The company's revenue growth has accelerated significantly, with a year-over-year increase of 605.4%. However, earnings growth figures are not available for comparison.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Visit website →Key Statistics
- Market Cap
- $469.52M
- P/E Ratio
- 17.74
- 52-Week High
- $13.16
- 52-Week Low
- $6.19
- Avg Volume
- 1.39M
- Beta
- 1.08
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 59